The Experts below are selected from a list of 3336 Experts worldwide ranked by ideXlab platform
Rene S Kahn - One of the best experts on this subject based on the ideXlab platform.
-
amisulpride and olanzapine followed by open label treatment with clozapine in first episode schizophrenia and Schizophreniform Disorder optimise a three phase switching study
The Lancet Psychiatry, 2018Co-Authors: Rene S Kahn, Inge Van Rossum, Stefan Leucht, Philip Mcguire, Shon Lewis, Marion Leboyer, Celso Arango, Paola DazzanAbstract:Summary Background No established treatment algorithm exists for patients with schizophrenia. Whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown. Methods This three-phase study was done in 27 centres, consisting of general hospitals and psychiatric specialty clinics, in 14 European countries and Israel. Patients aged 18–40 years who met criteria of the DSM-IV for schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder were treated for 4 weeks with up to 800 mg/day amisulpride orally in an open-label design (phase 1). Patients who did not meet symptomatic remission criteria at 4 weeks were randomly assigned to continue amisulpride or switch to olanzapine (≤20 mg/day) during a 6-week double-blind phase, with patients and staff masked to treatment allocation (phase 2). Randomisation was done online by a randomisation website; the application implemented stratification by site and sex, and applied the minimisation method for randomisation. Patients who were not in remission at 10 weeks were given clozapine (≤900 mg/day) for an additional 12 weeks in an open-label design (phase 3). The primary outcome was the number of patients who achieved symptomatic remission at the final visits of phases 1, 2, and 3, measured by intention-to-treat analysis. Data were analysed with a generalised linear mixed model, with a logistic link and binomial error distribution. This trial is registered with ClinicalTrials.gov , number NCT01248195 , and closed to accrual. Findings Between May 26, 2011, and May 15, 2016, we recruited 481 participants who signed informed consent. Of the 446 patients in the intention-to-treat sample, 371 (83%) completed open-label amisulpride treatment, and 250 (56%) achieved remission after phase 1. 93 patients who were not in remission continued to the 6-week double-blind switching trial, with 72 (77%) patients completing the trial (39 on olanzapine and 33 on amisulpride); 15 (45%) patients on amisulpride versus 17 (44%) on olanzapine achieved remission (p=0·87). Of the 40 patients who were not in remission after 10 weeks of treatment, 28 (70%) started on clozapine; 18 (64%) patients completed the 12-week treatment, and five (28%) achieved remission. The number of serious adverse events did not differ between the treatment arms in phase 2: one patient on olanzapine was admitted to hospital because of an epileptic seizure, and one patient on amisulpride was admitted to hospital twice because of exacerbations of psychotic symptoms. Over the course of the trial, two serious suicide attempts were reported. Interpretation For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine. Since switching to olanzapine did not improve outcome, clozapine should be used after patients fail a single antipsychotic trial—not until two antipsychotics have been tried, as is the current recommendation. Funding European Commission Seventh Framework Program.
-
effectiveness of antipsychotic drugs in first episode schizophrenia and Schizophreniform Disorder an open randomised clinical trial
The Lancet, 2008Co-Authors: Rene S Kahn, Michael Davidson, Silvana Galderisi, W. Wolfgang Fleischhacker, Han Boter, Ireneus P. M. Keet, Janusz K. Rybakowski, Yvonne Vergouwe, Mihai Dumitru Gheorghe, J LibigerAbstract:Summary Background Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. Methods We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Eligible patients were aged 18–40 years, and met diagnostic criteria for schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder. 498 patients were randomly assigned by a web-based online system to haloperidol (1–4 mg per day; n=103), amisulpride (200–800 mg per day; n=104), olanzapine (5–20 mg per day; n=105), quetiapine (200–750 mg per day; n=104), or ziprasidone (40–160 mg per day; n=82); follow-up was at 1 year. The primary outcome measure was all-cause treatment discontinuation. Patients and their treating physicians were not blinded to the assigned treatment. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN68736636. Findings The number of patients who discontinued treatment for any cause within 12 months was 63 (Kaplan-Meier estimate 72%) for haloperidol, 32 (40%) for amisulpride, 30 (33%) for olanzapine, 51 (53%) for quetiapine, and 31 (45%) for ziprasidone. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride (hazard ratio [HR] 0·37, [95% CI 0·24–0·57]), olanzapine (HR 0·28 [0·18–0·43]), quetiapine (HR 0·52 [0·35–0·76]), and ziprasidone (HR 0·51 [0·32–0·81]). However, symptom reductions were virtually the same in all the groups, at around 60%. Interpretation This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Funding AstraZeneca, Pfizer, Sanofi-Aventis.
-
focal gray matter density changes in schizophrenia
Archives of General Psychiatry, 2001Co-Authors: Hugo G Schnack, Rene C W Mandl, Neeltje E.m. Van Haren, Alan C. Evans, Hilde Koning, Louis D. Collins, Rene S KahnAbstract:Background The view that schizophrenia is a brain disease particularly involving decrements in gray matter is supported by findings from many imaging studies. However, it is unknown whether the (progressive) loss of tissue affects the brain globally or whether tissue loss is more prominent in some areas than in others. Methods Magnetic resonance whole brain images were acquired from 159 patients with schizophrenia or a Schizophreniform Disorder and 158 healthy subjects across a 55-year age span. Gray matter density maps were made and analyzed using voxel-based morphometry. Results Compared with healthy subjects, decreases in gray matter density were found in the left amygdala; left hippocampus; right supramarginal gyrus; thalamus; (orbito) frontal, (superior) temporal, occipitotemporal, precuneate, posterior cingulate, and insular cortices bilaterally in patients with schizophrenia or Schizophreniform Disorder. Compared with healthy subjects, increases in gray matter density were exclusively found in the right caudate and globus pallidus in patients with schizophrenia or Schizophreniform Disorder. A group-by-age interaction for density was found in the left amygdala, owing to a negative regression slope of gray matter density on age in the left amygdala in patients compared with healthy subjects. Conclusions Gray matter density is decreased in distinct focal areas in the brains of patients with schizophrenia or Schizophreniform Disorder. The decreased density in the left amygdala is more pronounced in older patients with schizophrenia.
Alan I. Green - One of the best experts on this subject based on the ideXlab platform.
-
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder.
The Journal of Clinical Psychiatry, 2007Co-Authors: Eduardo Dunayevich, Haya Ascher-svanum, Fangyi Zhao, Jennie G. Jacobson, Glenn Phillips, Mary Anne Dellva, Alan I. GreenAbstract:Objective: Time to all-cause treatment discontinuation is considered a composite proxy measure of treatment efficacy, safety, and tolerability. Longer time to discontinuation of antipsychotic medication for any cause has been shown to be associated with greater symptom improvements in the treatment of schizophrenia. This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes. Method: Using pooled data from 4 randomized, double-blind antipsychotic trials of 24- to 28-weeks' duration, this study examined the association between time to all-cause treatment discontinuation and functional outcomes, as assessed by a disease-specific, clinician-rated measure (Quality of Life Scale [QLS]) and a generic, patient-reported measure (Medical Outcomes Study Short Form 36 [SF-36]). Patients in these trials had a DSM-IV diagnosis of schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder. This post hoc analysis used Pearson partial correlations to assess relationships between time to treatment discontinuation and changes in functional scores, adjusting for baseline scores. Repeated measures analyses were also conducted to compare postbaseline functional outcome change over time between completers and noncompleters. Results: Longer time to all-cause treatment discontinuation was found to be significantly associated with greater improvements in all assessed functional domains (p
-
longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia Schizophreniform Disorder or schizoaffective Disorder
The Journal of Clinical Psychiatry, 2007Co-Authors: Eduardo Dunayevich, Fangyi Zhao, Jennie G. Jacobson, Glenn Phillips, Mary Anne Dellva, Haya Aschersvanum, Alan I. GreenAbstract:Objective: Time to all-cause treatment discontinuation is considered a composite proxy measure of treatment efficacy, safety, and tolerability. Longer time to discontinuation of antipsychotic medication for any cause has been shown to be associated with greater symptom improvements in the treatment of schizophrenia. This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes. Method: Using pooled data from 4 randomized, double-blind antipsychotic trials of 24- to 28-weeks' duration, this study examined the association between time to all-cause treatment discontinuation and functional outcomes, as assessed by a disease-specific, clinician-rated measure (Quality of Life Scale [QLS]) and a generic, patient-reported measure (Medical Outcomes Study Short Form 36 [SF-36]). Patients in these trials had a DSM-IV diagnosis of schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder. This post hoc analysis used Pearson partial correlations to assess relationships between time to treatment discontinuation and changes in functional scores, adjusting for baseline scores. Repeated measures analyses were also conducted to compare postbaseline functional outcome change over time between completers and noncompleters. Results: Longer time to all-cause treatment discontinuation was found to be significantly associated with greater improvements in all assessed functional domains (p <.05). Patients who completed their respective trials (46.8%, 761/1627) experienced significantly greater improvement in functional outcome measures (in 4 QLS domains and SF-36 mental health component summary score; all, p <.001) compared to patients who discontinued for any cause. In addition, greater symptom improvement was significantly associated with greater functional improvements in assessed domains. Conclusions: Findings from this post hoc analysis illustrate the importance of longer treatment duration with antipsychotics for improving functional outcomes in the treatment of patients with schizophrenia.
Yong Ku Kim - One of the best experts on this subject based on the ideXlab platform.
-
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder: 26-week prospective study
Psychiatry and Clinical Neurosciences, 2009Co-Authors: Jun Soo Kwon, Joon Hwan Jang, Do-hyung Kang, So Young Yoo, Yong Ku Kim, Seong-jin ChoAbstract:Aims: To date there have been no reports of long-term efficacy of aripiprazole in Asian populations. The aim of the present study was therefore to investigate the long-term efficacy, safety and tolerability of aripiprazole in a large number of patients with schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder in Korea. Methods: This study was a prospective, multicenter, single-group, 26-week open study of patients with schizophrenia, Schizophreniform Disorder, or schizoaffective Disorder. A total of 300 Korean patients participated in the study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures included the PANSS positive and negative subscales, Clinical Global Impression–Severity of Illness (CGI-S). Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests. Results: Aripiprazole produced rapid and significant improvements on all efficacy measures. As evidenced by PANSS total score, PANSS positive subscales and the CGI-S scores, first-episode drug-naive patients demonstrated significantly greater efficacy relative to patients who had previously experienced one or more episodes of relapse. Aripiprazole was associated with significant decrease of serum prolactin level. The subjects showed mild weight gain. Conclusion: Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. This study extends the findings of previous long-term studies, and has found that there is no significant difference with regard to ethnicity in response to aripiprazole.
-
efficacy and safety of long term aripiprazole therapy in patients with schizophrenia Schizophreniform Disorder and schizoaffective Disorder a 52 week prospective open label study
The Korean Journal of Psychopharmacology, 2008Co-Authors: Myung Hun Jung, Yong Ku Kim, Chang Yoon Kim, Chi Un Pae, Tak Youn, Minsoo Lee, Byung Ook Lee, Sunwoo Lee, Jong Il Lee, Bumseok JeongAbstract:Efficacy and Safety of Long-term Aripiprazole Therapy in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder: A 52-week, Prospective, Open-label Study Myung Hun Jung, MD, Yong Ku Kim, MD, Chang Yoon Kim, MD, PhD, Chi-Un Pae, MD, Tak Youn, MD, PhD, Min-Soo Lee, MD, PhD, Byung Ook Lee, MD, Sun Woo Lee, MD, PhD, Jong-Il Lee, MD, Bum Seok Jeong, MD, PhD, Seong-Jin Cho, MD, PhD and Jun Soo Kwon, MD, PhD Department of Psychiatry, Seoul National University College of Medicine, Seoul, Department of Psychiatry, Ansan Hospital, Korea University College of Medicine, Ansan, Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Department of Psychiatry, Kangnam St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Department of Psychiatry, Chonnam National University Medical School, Gwangju, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Seoul, Department of Psychiatry, National Health Insurance Corporation Ilsan Hospital, Goyang, Department of Psychiatry, Chungnam National University College of Medicine, Daejeon, Department of Psychiatry, Seoul National Hospital, Seoul, Department of Psychiatry, Eulji University College of Medicine, Daejeon, Department of Psychiatry, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea Objective:We investigated the long-term efficacy, safety, and tolerability of aripiprazole in a large number of patients with schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder in Korea. Methods:This 접수일:2008년 4월 15일 /수정일:2008년 5월 14일/게재확정일:2008년 6월 25일 This study was supported by Korea Otsuka Pharmaceutical Co., Ltd. (Seoul, Korea) 교신저자:권준수, 110-744 서울 종로구 연건동 28 서울대학교 의과대학 정신과학교실 전화:(02) 2072-2972·전송:(02) 747-9063 E-mail:kwonjs@plaza.snu.ac.kr
-
efficacy and safety of aripiprazole during acute treatment phase in patients with schizophrenia Schizophreniform Disorder and schizoaffective Disorder an 8 week prospective open label study
The Korean Journal of Psychopharmacology, 2008Co-Authors: Jung Seok Choi, Yong Ku Kim, D H Kim, J G Kim, Wonmyong Bahk, J G Cyn, B H Yoon, Jung Goo Lee, Dukin Jon, Y C ChungAbstract:Efficacy and Safety of Aripiprazole during Acute Treatment Phase in Patients with Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder:An 8-Week, Prospective, Open-Label Study Jung-Seok Choi, MD, Do Hoon Kim, MD, PhD, Yong Ku Kim, MD, Jeong Gee Kim, MD, PhD, Won-Myong Bahk, MD, PhD, Jae Gong Cyn, MD, Bo Hyun Yoon, MD, Jung Goo Lee, MD, PhD, Duk-In Jon, MD, PhD, Young Chul Chung, MD, PhD, Tak Youn, MD, PhD and Jun Soo Kwon, MD, PhD Department of Psychiatry, Seoul National University College of Medicine, Seoul, Department of Psychiatry, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Department of Psychiatry, Ansan Hospital, Korea University College of Medicine, Ansan, Department of Neuropsychiatry, Maryknoll General Hospital, Busan, Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Department of Psychiatry, Yong-In Mental Hospital, Yongin, Department of Psychiatry, Naju National Hospital, Naju, Paik Institute for Clinical Research, Inje University, Busan, Department of Psychiatry, Hallym University College of Medicine, Anyang, Department of Psychiatry, Chonbuk National University College of Medicine, Jeonju, Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea Objective:The purpose of the present study was to investigate the efficacy, safety, and tolerability of aripiprazole in patients with schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder during acute treatment phase. Methods:Prospective, multicenter, single group, and 8-week study was conducted in patients with schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder. A total of 300 patients were enrolled in the present study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures were the PANSS positive and negative subscales scores, and Clinical 접수일:2008년 4월 15일 / 수정일:2008년 5월 2일 / 게재확정일:2008년 5월 8일 This study was supported by Korea Otsuka Pharmaceutical Co., Ltd (Seoul, Korea). 교신저자:권준수, 110-744 서울 종로구 연건동 28번지 서울대학교 의과대학 정신과학교실 전화:(02) 2072-2972·전송:(02) 747-9063 E-mail:kwonjs@plaza.snu.ac.kr 아리피프라졸의 정신분열병 급성기 치료 Korean J Psychopharmacol 2008;19(3):147-155 148 Global Impression-Severity of Illness (CGI-S) score. Treatment-emergent adverse events, extrapyramidal symptoms (EPS), weight, vital signs, and laboratory tests were assessed as measures of tolerability and safety. Results: Significant improvements in all efficacy measures were achieved by aripiprazole as early as 1-week and sustained through 8-week period. First-episode patients showed greater improvements in PANSS total, positive subscale score, and CGI-S score, compared with recurrent patients. Slightly increased akathisia (+0.32 from baseline score of Barnes Akathisia Rating Scale, p=0.033) and weight gain (1.15±3.44 kg, p<0.001) were observed by aripiprazole during 8-week acute treatment phase. Conclusion:The present study demonstrated that aripiprazole was effective in acute treatment of positive and negative symptoms of schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder. In general, aripiprazole showed favorable safety and tolerability profiles, although clinicians needed to pay attention to the possibility of akathisia and weight gain by aripiprazole in first-episode patients during acute treatment phase. (Korean J Psychopharmacol 2008;19(3):147-155)
Y C Chung - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of aripiprazole during acute treatment phase in patients with schizophrenia Schizophreniform Disorder and schizoaffective Disorder an 8 week prospective open label study
The Korean Journal of Psychopharmacology, 2008Co-Authors: Jung Seok Choi, Yong Ku Kim, D H Kim, J G Kim, Wonmyong Bahk, J G Cyn, B H Yoon, Jung Goo Lee, Dukin Jon, Y C ChungAbstract:Efficacy and Safety of Aripiprazole during Acute Treatment Phase in Patients with Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder:An 8-Week, Prospective, Open-Label Study Jung-Seok Choi, MD, Do Hoon Kim, MD, PhD, Yong Ku Kim, MD, Jeong Gee Kim, MD, PhD, Won-Myong Bahk, MD, PhD, Jae Gong Cyn, MD, Bo Hyun Yoon, MD, Jung Goo Lee, MD, PhD, Duk-In Jon, MD, PhD, Young Chul Chung, MD, PhD, Tak Youn, MD, PhD and Jun Soo Kwon, MD, PhD Department of Psychiatry, Seoul National University College of Medicine, Seoul, Department of Psychiatry, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Department of Psychiatry, Ansan Hospital, Korea University College of Medicine, Ansan, Department of Neuropsychiatry, Maryknoll General Hospital, Busan, Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Department of Psychiatry, Yong-In Mental Hospital, Yongin, Department of Psychiatry, Naju National Hospital, Naju, Paik Institute for Clinical Research, Inje University, Busan, Department of Psychiatry, Hallym University College of Medicine, Anyang, Department of Psychiatry, Chonbuk National University College of Medicine, Jeonju, Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea Objective:The purpose of the present study was to investigate the efficacy, safety, and tolerability of aripiprazole in patients with schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder during acute treatment phase. Methods:Prospective, multicenter, single group, and 8-week study was conducted in patients with schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder. A total of 300 patients were enrolled in the present study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures were the PANSS positive and negative subscales scores, and Clinical 접수일:2008년 4월 15일 / 수정일:2008년 5월 2일 / 게재확정일:2008년 5월 8일 This study was supported by Korea Otsuka Pharmaceutical Co., Ltd (Seoul, Korea). 교신저자:권준수, 110-744 서울 종로구 연건동 28번지 서울대학교 의과대학 정신과학교실 전화:(02) 2072-2972·전송:(02) 747-9063 E-mail:kwonjs@plaza.snu.ac.kr 아리피프라졸의 정신분열병 급성기 치료 Korean J Psychopharmacol 2008;19(3):147-155 148 Global Impression-Severity of Illness (CGI-S) score. Treatment-emergent adverse events, extrapyramidal symptoms (EPS), weight, vital signs, and laboratory tests were assessed as measures of tolerability and safety. Results: Significant improvements in all efficacy measures were achieved by aripiprazole as early as 1-week and sustained through 8-week period. First-episode patients showed greater improvements in PANSS total, positive subscale score, and CGI-S score, compared with recurrent patients. Slightly increased akathisia (+0.32 from baseline score of Barnes Akathisia Rating Scale, p=0.033) and weight gain (1.15±3.44 kg, p<0.001) were observed by aripiprazole during 8-week acute treatment phase. Conclusion:The present study demonstrated that aripiprazole was effective in acute treatment of positive and negative symptoms of schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder. In general, aripiprazole showed favorable safety and tolerability profiles, although clinicians needed to pay attention to the possibility of akathisia and weight gain by aripiprazole in first-episode patients during acute treatment phase. (Korean J Psychopharmacol 2008;19(3):147-155)
Bumseok Jeong - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of long term aripiprazole therapy in patients with schizophrenia Schizophreniform Disorder and schizoaffective Disorder a 52 week prospective open label study
The Korean Journal of Psychopharmacology, 2008Co-Authors: Myung Hun Jung, Yong Ku Kim, Chang Yoon Kim, Chi Un Pae, Tak Youn, Minsoo Lee, Byung Ook Lee, Sunwoo Lee, Jong Il Lee, Bumseok JeongAbstract:Efficacy and Safety of Long-term Aripiprazole Therapy in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder: A 52-week, Prospective, Open-label Study Myung Hun Jung, MD, Yong Ku Kim, MD, Chang Yoon Kim, MD, PhD, Chi-Un Pae, MD, Tak Youn, MD, PhD, Min-Soo Lee, MD, PhD, Byung Ook Lee, MD, Sun Woo Lee, MD, PhD, Jong-Il Lee, MD, Bum Seok Jeong, MD, PhD, Seong-Jin Cho, MD, PhD and Jun Soo Kwon, MD, PhD Department of Psychiatry, Seoul National University College of Medicine, Seoul, Department of Psychiatry, Ansan Hospital, Korea University College of Medicine, Ansan, Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Department of Psychiatry, Kangnam St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Department of Psychiatry, Chonnam National University Medical School, Gwangju, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Seoul, Department of Psychiatry, National Health Insurance Corporation Ilsan Hospital, Goyang, Department of Psychiatry, Chungnam National University College of Medicine, Daejeon, Department of Psychiatry, Seoul National Hospital, Seoul, Department of Psychiatry, Eulji University College of Medicine, Daejeon, Department of Psychiatry, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea Objective:We investigated the long-term efficacy, safety, and tolerability of aripiprazole in a large number of patients with schizophrenia, Schizophreniform Disorder, and schizoaffective Disorder in Korea. Methods:This 접수일:2008년 4월 15일 /수정일:2008년 5월 14일/게재확정일:2008년 6월 25일 This study was supported by Korea Otsuka Pharmaceutical Co., Ltd. (Seoul, Korea) 교신저자:권준수, 110-744 서울 종로구 연건동 28 서울대학교 의과대학 정신과학교실 전화:(02) 2072-2972·전송:(02) 747-9063 E-mail:kwonjs@plaza.snu.ac.kr
